AZD2716 is an investigational small-molecule drug developed by AstraZeneca. It is a selective BET (bromodomain and extraterminal domain) protein inhibitor, particularly targeting BRD4, which plays a key role in regulating gene transcription linked to inflammation and cancer. AZD2716 is under evaluation for its anti-inflammatory and anti-fibrotic properties, especially in diseases such as chronic obstructive pulmonary disease (COPD) and fibrosis-related conditions.
MedKoo Cat#: 522574
Name: AZD2716
CAS#: 1845753-81-2
Chemical Formula: C24H23NO3
Exact Mass: 373.1678
Molecular Weight: 373.45
Elemental Analysis: C, 77.19; H, 6.21; N, 3.75; O, 12.85
The following data is based on the product molecular weight 373.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
